Terms: = Lung cancer AND SETD2, ENSG00000181555, 29072 AND Prognosis
10 results:
1. METTL3 exerts synergistic effects on m6A methylation and histone modification to regulate the function of VGF in lung adenocarcinoma.
Shi K; Sa R; Dou L; Wu Y; Dong Z; Fu X; Yu H
Clin Epigenetics; 2023 Sep; 15(1):153. PubMed ID: 37742030
[TBL] [Abstract] [Full Text] [Related]
2. setd2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy.
Zheng X; Lin J; Xiong J; Guan Y; Lan B; Li Y; Gao X; Fei Z; Chen L; Chen L; Chen L; Chen G; Guo Z; Yi X; Cao W; Ai X; Zhou C; Li X; Zhao J; Yan X; Yu Q; Si L; Chen Y; Chen C
BMC Cancer; 2023 Jul; 23(1):686. PubMed ID: 37479966
[TBL] [Abstract] [Full Text] [Related]
3. Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies.
Dietz MV; van Kooten JP; Paats MS; Aerts JGVJ; Verhoef C; Madsen EVE; Dubbink HJ; von der Thüsen JH
ESMO Open; 2023 Aug; 8(4):101600. PubMed ID: 37453150
[TBL] [Abstract] [Full Text] [Related]
4. A combination of intrinsic and extrinsic features improves prognostic prediction in malignant pleural mesothelioma.
Nguyen TT; Lee HS; Burt BM; Amos CI; Cheng C
Br J Cancer; 2022 Nov; 127(9):1691-1700. PubMed ID: 35999269
[TBL] [Abstract] [Full Text] [Related]
5. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms.
Venizelos A; Elvebakken H; Perren A; Nikolaienko O; Deng W; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Krogh M; Sorbye H; Knappskog S
Endocr Relat Cancer; 2021 Nov; 29(1):1-14. PubMed ID: 34647903
[TBL] [Abstract] [Full Text] [Related]
6. [Expression and clinical significance of setd2 in maligant pleural mesothelioma].
Yu M; Yu M; Zhu LJ; Yuan XY; Zhang X
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Feb; 39(2):91-98. PubMed ID: 33691361
[No Abstract] [Full Text] [Related]
7. Genetic alterations in squamous cell lung cancer associated with idiopathic pulmonary fibrosis.
Hata A; Nakajima T; Matsusaka K; Fukuyo M; Nakayama M; Morimoto J; Ito Y; Yamamoto T; Sakairi Y; Rahmutulla B; Ota S; Wada H; Suzuki H; Iwata T; Matsubara H; Ohara O; Yoshino I; Kaneda A
Int J Cancer; 2021 Jun; 148(12):3008-3018. PubMed ID: 33533494
[TBL] [Abstract] [Full Text] [Related]
8. Gender differences in molecular-guided therapy recommendations for metastatic malignant mesothelioma.
Taghizadeh H; Zöchbauer-Müller S; Mader RM; Müllauer L; Klikovits T; Bachleitner-Hofmann T; Hoda MA; Prager GW
Thorac Cancer; 2020 Jul; 11(7):1979-1988. PubMed ID: 32438515
[TBL] [Abstract] [Full Text] [Related]
9. Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival.
Quetel L; Meiller C; Assié JB; Blum Y; Imbeaud S; Montagne F; Tranchant R; de Wolf J; Caruso S; Copin MC; Hofman V; Gibault L; Badoual C; Pintilie E; Hofman P; Monnet I; Scherpereel A; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
Mol Oncol; 2020 Jun; 14(6):1207-1223. PubMed ID: 32083805
[TBL] [Abstract] [Full Text] [Related]
10. Novel molecular targets for the treatment of lung cancer.
Rosell R; Karachaliou N; Arrieta O
Curr Opin Oncol; 2020 Jan; 32(1):37-43. PubMed ID: 31599770
[TBL] [Abstract] [Full Text] [Related]
